Graft-versus-Host Disease (GvHD) - An update. Part 2: Prognosis and therapy of GvHD;Graft-versus-Host-Disease (GvHD) - Ein update. Teil 2: Prognose und therapie der GvHD

Hautarzt

Volumn 62, Issue 3, 2011, Pages 229-239

  Travnik, R ^a   Beckers, M ^a   Wolff, D ^b   Holler, E ^b   Landthaler, M ^a   Karrer, S ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Acute GvHD; Chronic GvHD; Extracorporeal photopheresis; mTOR inhibitors; Stem cell transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; METHOTREXATE; RAPAMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE CLASSIFICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOCOMPATIBILITY; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVENTION STUDY; PROGNOSIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN CANCER; SKIN DISEASE; SKIN MANIFESTATION; TREATMENT PLANNING;

ADRENAL CORTEX HORMONES; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; OPPORTUNISTIC INFECTIONS; PHOTOPHERESIS; PHOTOSENSITIVITY DISORDERS; PROGNOSIS; RISK FACTORS; SCLERODERMA, LOCALIZED; SKIN DISEASES; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TOR SERINE-THREONINE KINASES;

EID: 79955581182     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-010-2118-1     Document Type: Review

References (22)

1. Arai S, Vogelsang GB (2000) Management of graft-versus-host disease. Blood Rev 14:190-204 (Pubitemid 32098008)
2. Carcagni MR, De Aloe G, D'Ascenzo G et al (2008) Extracorporeal photopheresis in graft-versus-host disease. J Dtsch Dermatol Ges 6:451-457 (Pubitemid 351740396)
3. Elad S, Or R, Resnick I, Shapira MY (2003) Topical tacrolimus - a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 16:665-670 (Pubitemid 37193295)
4. Ferrara JL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324:667-674
5. Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956 (Pubitemid 41754712)
6. Gatza E, Rogers CE, Clouthier SG et al (2008) Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112:1515-1521
7. Grauer O, Wolff D, Bertz H et al (2010) Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 133:2852-2865
8. Greinix HT, Knobler RM, Worel N et al (2006) The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91:405-408
9. Greinix HT, Loddenkemper C, Pavletic SZ et al (2010) Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant [Epub ahead of print]
10. Hausermann P, Walter RB, Halter J et al (2008) Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 216:287-304 (Pubitemid 351630093)
11. Jacobsohn DA, Vogelsang GB (2002) Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 62:879-889 (Pubitemid 34454615)
12. Just U, Knobler R (2009) Extracorporeal photopheresis. Hautarzt 60:337-343; quiz 344
13. Leisenring W, Friedman DL, Flowers ME et al (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24:1119-1126 (Pubitemid 46638809)
14. Martin PJ, Storer BE, Rowley SD et al (2009) Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 113:5074-5082
15. Rizzo JD, Curtis RE, Socie G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175-1183
16. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ (2007) Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:2-10 (Pubitemid 46044113)
17. Vargas-Diez E, Garcia-Diez A, Marin A, Fernandez-Herrera J (2005) Life-threatening graft-vs-host disease. Clin Dermatol 23:285-300 (Pubitemid 40724462)
18. Vogelsang GB (2001) How I treat chronic graft-versus-host disease. Blood 97:1196-1201
19. Wolff D, Gerbitz A, Ayuk F et al (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 16:1611-1628
20. Wolff D, Schleuning M, Harsdorf S von et al (2011) Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 17:1-17
21. Wolff D, Steiner B, Hildebrandt G et al (2009) Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des 15:1974-1997
22. Wolff D, Bertz H, Greinix H et al (im Review) Klinische Praxis der chronischen GvHD - ein Expertenkonsens aus Deutschland, Österreich und der Schweiz. Dtsch Arztebl